臨床泌尿器科61巻5号

2007年04月発行

特集 腎細胞癌診療の新しい展開

分子標的薬剤の開発状況

著者： 河合弘二¹

所属機関： ¹筑波大学大学院人間総合科学研究科，臨床医学系泌尿器科

ページ範囲：P.309 - P.315

要旨　腎細胞癌に対する分子標的薬剤の開発は急速に進み，既存のサイトカイン療法を凌ぐ成果も得られつつある。わが国においても近い将来，分子標的薬剤が進行期腎癌の治療体系に組み込まれてくると考えられる。本稿では最近，第Ⅲ相臨床試験の結果が報告されたマルチキナーゼ阻害剤，mTOR阻害剤を中心に腎癌に対する分子標的薬剤の現状についてまとめた。

参考文献

1）Motzer RJ, Michaelson D, Redman BG, et al：Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastaic renal cell carcinoma. J Clin Oncol 24：16-24, 2006

2）Motzer RJ, Rini BI, Bukowski RM, et al：Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295：2516-2524, 2006

3）Ratain MJ, Eisen T, Stadler WM, et al：PhaseⅡ placebo-controlled randomized discontinuation trial of sorafenib in patients with metasattic renal cell carcinoma. J Clin Oncol 24：2505-2512, 2006

4）Rini B, Rixe O, Bukowski R, et al：AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer（RCC）. Proc Am Soc Clin Oncol 23：380S, 2005（abstarct 4509）

5）Motzer RJ, Hutson TE, Tomczak P, et al：Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356：115-124, 2007

6）Motzer RJ, Bacik J, Murphy BA, et al：Interferon-alfa as a comparative treatment for clinical trial of new therapies against advanced renal cell carcinoma. J Clin Oncol 20：289-296, 2001

7）Escudier B, Eisen T, Stadler WM, et al：Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356：115-124, 2007

8）Rini BI, Tamaskar I, Shaheen P, et al：Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Nath Cancer Inst 99：81-83, 2007

9）Atkins MB, Hidalgo M, Stadler WM, et al：Randomized phaseⅡ study of mutiple dose levels of CCI-779, a novel mamalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22：909-918, 2004

10）Hudes G, Carducci M, Tomczak P, et al：A phase 3, randomized, 3-arm study of temsirolimus（TEMSR）or interferon-alpha（IFN）or the combination of TEMSR＋IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma（adv RCC）. Proc Am Soc Clin Oncol 24：18S, 2006（abstarct LBA4）

11）Amato RJ, Misellati A, Khan M, et al：A phaseⅡ trial of RAD001 in patients（Pts）with metastatic renal cell carcinoma（MRCC）. Proc Am Soc Clin Oncol 24：18S, 2006（abstarct 4530）

12）Drucker B, Bacik J, Ginsberg M, et al：PhaseⅡ trial of ZD1839（IRESSA）in patients with advanced renal cell carcinoma. Invest New Drugs 21：341-345, 2003

13）Dawson NA, Guo C, Zak R, et al：A phaseⅡ trial of Gefitinib（Iressa, ZD1839）in stageⅣ and recurrent renal cell carcinoma. Clin Cancer Res 10：7812-7819, 2004

14）Jermann M, Stahel RA, Salzberg M, et al：A phaseⅡ, open-label study of gefitinib（IRESSA）in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma. Cancer Chemother Pharmacol 29：1-7, 2005

15）Lynch TJ, Bell DW, Sordella R, et al：Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to Gefitinib. N Engl J Med 350：2129-2139, 2004

16）Sordella R, Bell DW, Haber DA, et al：Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305：1163-1167, 2004

17）Sakaeda T, Okumura N, Gotoh A, et al：EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients. Pharma Res 22：1757-1761, 2005

18）Beeram M, Rowinsky EK, Weiss GR, et al：Durable disease stabilization and antitumor activity with OSI-774 in renal cell carcinoma：a phaseⅡ, pharmacokinetics and biological correlative study with FDG-PET imaging. Proc Am Soc Clin Oncol 23：207, 2004（abstarct 3050）

19）Yang JC, Haworth L, Sherry RM, et al：A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349：427-434, 2003

20）Kondagunta GV, Drucker B, Schwartz L, et al：PhaseⅡ trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22：3720-3725, 2004

21）Bellmunt J, Montagut C, Albiol S, et al：Present strategies in the treatment of metastatic renal cell carcinoma：an update on molecular targeting agents. BJU International 2006 Dec 1；Epub ahead of print